Section Arrow
KARD.NASDAQ
- Kardigan Inc
Quotes are at least 15-min delayed:2026/11/08 00:44 EST
Regular Hours
Last
 15.52
+1.66 (+11.98%)
Day High 
15.56 
Prev. Close
13.86 
1-M High
15.93 
Volume 
406.63K 
Bid
13
Ask
16.6
Day Low
13.571 
Open
14 
1-M Low
12.23 
Market Cap 
1.30B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 13.92 
20-SMA 13.68 
50-SMA 15.82 
52-W High 27 
52-W Low 12.23 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-3.09/-3.49
Enterprise Value
1.31B
Balance Sheet
Book Value Per Share
6.58
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
KPTIKaryopharm Therapeutics Inc.0.0549-0.0052-8.65%-- 
INOInovio Pharmaceuticals1.215-0.235-16.21%-- 
LABTLakewood-Amedex Biotherapeutics Inc0.3863-0.1543-28.54%-- 
CDTCdt Equity Inc1.31+0.464+54.85%0PE
MRNAModerna254.19+12.73+5.27%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Kardigan Inc is a clinical-stage therapeutics company focused on developing medicines for cardiovascular diseases. Its activities include the research and development of targeted therapies for cardiovascular conditions for which no approved treatments currently exist. The company's clinical-stage programs include Danicamtiv, Ataciguat, and Tonlamarsen, which are being developed for cardiovascular disease indications. The company operates and manages its business as a singleoperating and reportable segment, focused on the discovery and development of novel therapeutic products to treat cardiovascular disease.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.